Regencell Bioscience
3 hedge funds and large institutions have $316K invested in Regencell Bioscience in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.09% more ownership
Funds ownership: 0% → 4.09% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$175K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$56.1K |
| 3 |
Morgan Stanley
New York
|
+$8.62K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
1
Schonfeld Strategic Advisors
New York
| $231K | +$175K | +387,600 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $74K | +$56.1K | +124,260 | New |
|
|
3
Morgan Stanley
New York
| $11K | +$8.62K | +19,114 | New |
|
RGC Hedge Fund Activity: Q3 2021 in Review
3 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q3 2021, worth a combined $316K.
Buyers outnumbered sellers: 3 funds opened new RGC positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $175K.
- 3 institutional investors held Regencell Bioscience (RGC) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $316K of Regencell Bioscience stock for Q3 2021.
- 3 funds opened new Regencell Bioscience positions in Q3 2021 and 0 closed out, a net change of +3 holders.
- The largest Regencell Bioscience buyer in Q3 2021 was Schonfeld Strategic Advisors, an estimated $175K added.
Based on aggregated 13F filings for Q3 2021.